Anuj Jayakar
Neurology with Special Qualifications in Child Neurology · Miami, FLNPI 1609125905
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Neurelis, Inc. at 45.9% of the total.
Across 511 payments — averaging $46.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$11K
- UCB, Inc.$4K
- Jazz Pharmaceuticals Inc.$3K
- Sunovion Pharmaceuticals Inc.$2K
- Aquestive Therapeutics, Inc.$530
- Eisai Inc.$443
- plus $3K from 31 others
Across 35 payments — averaging $9650.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$309K
- Immedica Pharma US, Inc.$18K
- UCB Biosciences Inc.$10K
- UCB, Inc.$820
What the payments were for
- Consulting fees$7,91133%
- Speaking & faculty fees$1,4966%
- Travel & lodging$1,0654%
- Food & beverage$13,20256%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 105 | $10,868 |
| UCB, Inc. | 103 | $4,295 |
| Jazz Pharmaceuticals Inc. | 84 | $2,697 |
| Sunovion Pharmaceuticals Inc. | 26 | $2,051 |
| Aquestive Therapeutics, Inc. | 30 | $530 |
| Eisai Inc. | 34 | $443 |
| Sumitomo Pharma America, Inc. | 13 | $323 |
| Corium, LLC | 17 | $304 |
| Livanova USA, Inc. | 15 | $300 |
| Ironshore Pharmaceuticals Inc. | 13 | $192 |
| Biogen | 7 | $159 |
| Biocodex, Inc. | 5 | $157 |
| Zogenix Inc. | 5 | $140 |
| Kyowa Kirin, Inc. | 1 | $137 |
| SK Life Science, Inc. | 6 | $125 |
| Catalyst Pharmaceuticals, Inc. | 6 | $112 |
| Aprecia Pharmaceuticals, LLC | 6 | $90 |
| Azurity Pharmaceuticals, Inc. | 4 | $88 |
| Immedica Pharma US, Inc. | 4 | $88 |
| Biomarin Pharmaceutical Inc. | 1 | $69 |
| Novartis | 4 | $61 |
| NS Pharma, Inc. | 3 | $48 |
| Aucta Pharmaceuticals, Inc. | 2 | $46 |
| Upsher-smith Laboratories LLC | 2 | $46 |
| AbbVie | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Sarepta Therapeutics, Inc. | 1 | $29 |
| Acadia Pharmaceuticals Inc | 1 | $26 |
| Greenwich Biosciences, Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| ITF Therapeutics LLC | 1 | $21 |
| Saol Therapeutics Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Piramal Critical Care | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,674 in reported general payments places this provider in the 80th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Miami
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ian MillerMiami$104K
- Matt LallasMiami$88K
- Marytery FajardoMiami$44K
- Paula SchleiferMiami$31K
- Roberto Lopez-AlberolaMiami$31K
- Walter BradleyMiami$19K
- Yashira Torres RamirezMiami$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.